Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a retrospective review of treatment of patients with aggressive lymphoma who had relapsed after stem cell transplantation, single-agent rituximab was shown to induce complete or partial responses in close to 50% of patients. This compares favorably to salvage chemotherapy as reported in prior series.

Rituximab for Relapsed Lymphoma after Autologous Transplant